The Bamlanivimab+Etesevimab are anti-SARC-COVID-2 monoclonal antibodies which have received Emergency Use Authorization (EUA) from US FDA as well as conditional use approval from the MoHP, Department of Drug Administration (DDA) in Nepal.
Latest Public Health Jobs
Latest Posts
- International Vaccinology Course and Fellowship 2025
- National Tuberculosis Patient Cost Survey in Nepal 2024
- LSTM and HERD International PhD Fellowship Opportunity
- World Malaria Day 2025: Malaria Ends with Us: Reinvest, Reimagine, Reignite
- World Immunization Week 2025: Immunization for All is Humanly Possible
Thanks for visiting us.
Disclaimer: The resources, documents, guidelines, and information on this blog have been collected from various sources and are intended for informational purposes only. Information published on or through this website and affiliated social media channels does not represent the intention, plan, or strategies of an organization that the initiator is associated with in a professional or personal capacity, unless explicitly indicated.
If you have any complaints, information, or suggestions about the content published on Public Health Update, please feel free to contact us at blog.publichealthupdate@gmail.com.
#StayUpdated
